Warren Brandon C, Yadav Harika, Graham Matthew, Tudor Maria
Internal Medicine, University of Tennessee, Chattanooga, USA.
Hematology/Oncology, Tennessee Oncology, Chattanooga, USA.
Cureus. 2022 Apr 21;14(4):e24360. doi: 10.7759/cureus.24360. eCollection 2022 Apr.
Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threateningly aggressive syndrome caused by excessive immune activation. It involves the abnormal activation of lymphocytes and macrophages which leads to tissue destruction and inflammation. Traditionally HLH classification is currently separated into primary and secondary HLH based on genetic versus nongenetic events such as infection, malignancy, or autoimmune disorders. In this case report, we present the case of a middle-aged woman presenting with HIV with medication noncompliance who presented to the emergency department with pancytopenia as well as disseminated histoplasmosis and was diagnosed with HLH based on the HLH-2004 guidelines and treated in accordance with the HLH-94 protocol. The patient also underwent treatment for the management of her histoplasmosis with a favorable outcome. This case demonstrates that HLH is best treated through management of the underlying process that triggered the syndrome such as infection as in this patient in addition to management per HLH-94 protocol early on in the course of the disease in order to have the best chance at a positive clinical outcome.
噬血细胞性淋巴组织细胞增生症(HLH)是一种由过度免疫激活引起的罕见且具有致命侵袭性的综合征。它涉及淋巴细胞和巨噬细胞的异常激活,进而导致组织破坏和炎症。传统上,HLH分类目前基于遗传与非遗传事件(如感染、恶性肿瘤或自身免疫性疾病)分为原发性和继发性HLH。在本病例报告中,我们呈现了一名中年女性的病例,该女性患有HIV且不遵医嘱服药,因全血细胞减少以及播散性组织胞浆菌病就诊于急诊科,并根据HLH - 2004指南被诊断为HLH,并按照HLH - 94方案进行治疗。该患者还接受了组织胞浆菌病的治疗,结果良好。本病例表明,HLH最好通过治疗引发该综合征的潜在过程(如本病例中的感染)来进行治疗,此外,在疾病早期按照HLH - 94方案进行治疗,以便获得最佳的积极临床结果。